SPY411.49+2.97 0.73%
DIA337.86+2.73 0.81%
IXIC13,900.19+70.88 0.51%

Alimera Sciences Says Achieves Extended Reimbursement In Ireland

Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmology treatments for the management of retinal

· 03/17/2021 08:16

Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces continued execution on its geographic expansion strategy with publication of ILUVIEN pricing in Denmark and Luxembourg. In addition, the Company received approval for reimbursement for the prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS) from the three largest private health insurers in Ireland.

"Alimera continues to make incremental progress on our global expansion strategy, regularly receiving approval for distribution and reimbursement by the regulatory authorities in new countries, despite the fact that we continue to feel the effects of the global pandemic of COVID-19," stated Rick Eiswirth, Alimera's President and CEO. "While the health status may vary country by country, presenting challenges to those doctors trying to prescribe ILUVIEN to their patients, we continue to receive the consistent message from both the healthcare professionals and the regulatory authorities reviewing our applications that ILUVIEN has a measurable impact on patients."

In March, the price of ILUVIEN was made public in Denmark where ILUVIEN is approved for both the DME and NIU-PS indications. Earlier in the quarter, Luxembourg's Ministry of Health approved ILUVIEN for reimbursement for DME. In Ireland, the three largest private insurers, which together represent approximately 50% of covered lives in the country, also recently approved ILUVIEN for reimbursement in private hospitals under its health plans. The Company is still waiting for the public health system to grant reimbursement.